What Minerva Biotechnologies does

Minerva Biotechnologies is a privately held, clinical-stage biotechnology company founded in 1999 and headquartered in Waltham, Massachusetts, with approximately 20 employees. The company operates two integrated therapeutic platforms: a cancer immunotherapy franchise built around the MUC1* cancer-specific growth factor receptor — a novel target expressed on roughly 75% of solid tumors and over 95% of breast cancers — and a regenerative medicine platform based on NME7AB-induced naive stem cells and the AlphaSTEM reagent product line. Its lead oncology assets are huMNC2-CAR44, currently in a Phase I/II trial in MUC1*-positive breast cancer, and MUC1*-CAR22, for which the company holds an FDA-approved IND. The CAR T constructs incorporate 1XX mutations in the CD3zeta cytoplasmic domain, technology licensed from Memorial Sloan Kettering Cancer Center and co-invented by Scientific Advisory Board member Michel Sadelain.

The company's technology base rests on proprietary targeting of the cleaved/activated form of MUC1 (MUC1*), which is described as driving tumor growth and metastasis, and on the AlphaSTEM/NME7AB system that enables homogeneous naive-like stem cell populations for GMP-compliant manufacture of patient-derived mesenchymal stem cells. Minerva has published peer-reviewed data in the Journal for ImmunoTherapy of Cancer and PLOS One in 2025 supporting CAR T persistence in heterogeneous solid tumors and differentiation efficiency of NME7AB-induced stem cells.

Commercially, Minerva is pre-revenue on its therapeutic programs and pursues a partnership-led business model, actively seeking pharmaceutical licensing deals, co-development arrangements for ADC and bispecific antibody approaches, and clinical collaborators. The company also sells AlphaSTEM stem cell research reagents directly via its ecommerce website (minervabio.com) to academic and biotech research buyers. The company is led by CEO Dr. Cynthia Bamdad and has been funded through SEC-registered exempt offerings and prior private rounds totaling approximately $70 million in disclosed capital since 2010.

Name

Minerva Biotechnologies

Legal name

Minerva Biotechnologies Corporation

Website

https://minervabio.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Minerva Biotechnologies is a clinical-stage biotech developing MUC1*-targeted CAR T immunotherapies for solid tumors and an NME7AB-based regenerative stem cell platform, serving pharmaceutical licensing partners and research institutions via its AlphaSTEM ecommerce channel.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Cancer immunotherapy
• CAR T therapy
• Regenerative medicine
• Stem cell reagents
• Cell therapy development

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Biopharmaceutical Licensing and Partnership Deals: Minerva seeks pharmaceutical partners to license its regenerative medicine platform for any cell type, to co-develop ADC or bispecific antibody approaches, and to accelerate CAR T trials in additional cancer indications. Revenue is generated through upfront licensing fees, milestone payments, and potential royalties on approved therapies.
2. Stem Cell Research Reagent Sales: Minerva sells stem cell research products including AlphaSTEM reagents through its ecommerce website (minervabio.com). These products are sold to research institutions, biotechnology companies, and pharmaceutical companies engaged in regenerative medicine research.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Minerva Biotechnologies is a clinical-stage biopharmaceutical company developing cancer immunotherapies (CAR T therapies targeting the cancer-specific MUC1* receptor) for solid tumors and a regenerative medicine platform built on NME7AB-induced naive stem cells. It also sells AlphaSTEM stem cell research reagents via its ecommerce site to research institutions and biotech companies.

Product overview

Minerva Biotechnologies is a clinical-stage biotechnology company developing two integrated therapeutic platforms: cancer immunotherapies and regenerative medicine. The cancer therapeutics platform centers on CAR T therapies (huMNC2-CAR44, MUC1*-CAR22) targeting MUC1* positive solid tumors, while the regenerative medicine platform utilizes AlphaSTEM® reagents and NME7AB technology for GMP-compliant manufacture of patient-derived stem cells. The company's therapeutic pipeline includes CAR T therapies for breast cancer (Phase I/II), next-generation CARs, monoclonal antibody approaches, and stem cell-derived cell therapies for regenerative applications.

Differentiator

Problem solved

Functional benefit

Brands

• AlphaSTEM: iPSC generation technology that is more efficient with faster cell expansion and increased differentiation efficiency.

Products and services

• AlphaSTEM®
• huMNC2-CAR44
• MUC1*-CAR22
• MUC1* Antibody Panel
• Regenerative Medicine Platform (licensing)

Quantifiable outcome

• MUC1* CAR-1XX T cells showed increased persistence and suppressed tumor recurrence in animal models against heterogeneous tumors with low antigen-expressing cancer cells
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Memorial Sloan Kettering Cancer CentercoreTechnology or IntegrationMinerva licensed the 1XX CAR T technology from Memorial Sloan Kettering Cancer Center. Dr. Michel Sadelain (inventor of 1XX technology and 2024 Breakthrough Prize laureate in Life Sciences) is an active member of Minerva's Scientific Advisory Board. This technology is central to Minerva's CAR T programs for solid tumors.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered T-cell receptors (TCR-T) and next-gen CAR-T approaches for solid tumors. Highly comparable in modality (engineered autologous T cells), target patient population (solid tumor cancer patients), and clinical-stage profile facing the same solid-tumor efficacy challenges Minerva is targeting with MUC1*-CAR T.
• Fate Therapeutics: Clinical-stage biotech developing iPSC-derived cell therapies including NK and T-cell candidates for cancer. Direct overlap with Minerva's regenerative medicine platform (NME7AB-induced naive stem cells for iPSC generation and differentiation) and shared interest in scalable, off-the-shelf cell therapy manufacturing.
• Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies using CRISPR-edited platforms. Comparable as a peer clinical-stage CAR-T developer targeting hematologic and solid tumors with engineered T-cell therapies, competing for the same pharma partnership and licensing capital.
• Allogene Therapeutics: Clinical-stage biotech developing allogeneic CAR-T therapies for cancer. Direct peer in modality and clinical stage, addressing the same engineered T-cell therapy market, though focused on hematologic malignancies and off-the-shelf delivery while Minerva is autologous and focused on solid tumors.
• Poseida Therapeutics: Clinical-stage cell and gene therapy company developing CAR-T and other engineered T-cell therapies, including allogeneic candidates. Comparable as a small clinical-stage cell therapy biotech pursuing CAR-T programs for cancer with novel engineering approaches to address persistence and solid-tumor challenges.
• Century Therapeutics: Clinical-stage biotech developing iPSC-derived allogeneic cell therapies including CAR-T and NK cell candidates. Direct overlap with Minerva's iPSC-derived regenerative medicine and engineered T-cell platforms; both companies leverage stem cell engineering to produce next-generation cancer immunotherapies.
• Atara Biotherapeutics: Clinical-stage cell therapy company developing allogeneic T-cell and CAR-T therapies for cancer and autoimmune diseases. Peer clinical-stage cell therapy developer with comparable trial-stage assets and strategic focus on licensing and partnership-based commercialization.

Emerging players

• Cellectis: Clinical-stage gene-editing and cell therapy company developing allogeneic CAR-T therapies using TALEN-based gene editing. Comparable as a CAR-T developer pursuing engineering innovations to improve persistence and overcome solid-tumor barriers, though with broader gene-editing platform exposure beyond cancer.

Broad incumbents

• BioNTech: Large clinical-to-commercial biopharmaceutical company developing mRNA-based immunotherapies, engineered cell therapies (including CAR-T), and antibody-based cancer treatments. Overlapping capability space with Minerva's CAR-T and antibody programs targeting solid tumors, though with substantially broader portfolio and commercialization scale.
• Gilead (Kite Pharma): Established leader in autologous CAR-T cell therapy with multiple FDA-approved products (Yescarta, Tecartus, Breyanzi) for hematologic malignancies, now expanding into solid tumor programs. Relevant as the dominant incumbent in CAR-T commercial development and a natural potential licensing/partnering counterparty for Minerva's MUC1* CAR-T programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MinervaBio
• Facebookfacebook.com/1241207610
• LinkedInlinkedin.com/company/minerva-biotechnologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds7 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minerva Biotechnologies